213 related articles for article (PubMed ID: 11043855)
1. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.
Yudkin JS; Panahloo A; Stehouwer C; Emeis JJ; Bulmer K; Mohamed-Ali V; Denver AE
Diabetologia; 2000 Sep; 43(9):1099-106. PubMed ID: 11043855
[TBL] [Abstract][Full Text] [Related]
2. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
4. Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
Ebeling P; Heliövaara MK
Diabetologia; 2001 Apr; 44(4):519-20. PubMed ID: 11357487
[No Abstract] [Full Text] [Related]
5. Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
Fernandez-Real JM; Ricart W
Diabetologia; 2001 Apr; 44(4):518-9. PubMed ID: 11357486
[No Abstract] [Full Text] [Related]
6. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.
Schalkwijk CG; Poland DC; van Dijk W; Kok A; Emeis JJ; Dräger AM; Doni A; van Hinsbergh VW; Stehouwer CD
Diabetologia; 1999 Mar; 42(3):351-7. PubMed ID: 10096789
[TBL] [Abstract][Full Text] [Related]
8. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
9. Correction of hyperglycaemia reduces insulin resistance and serum soluble E-selectin levels in patients with Type 2 diabetes mellitus.
Matsumoto K; Nakamura H; Ueki Y; Tominaga T; Miyake S
Diabet Med; 2001 Mar; 18(3):224-8. PubMed ID: 11318844
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
Pearson ER; Liddell WG; Shepherd M; Corrall RJ; Hattersley AT
Diabet Med; 2000 Jul; 17(7):543-5. PubMed ID: 10972586
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
Harashima SI; Ogura M; Tanaka D; Fukushima T; Wang Y; Koizumi T; Aono M; Murata Y; Seike M; Inagaki N
Int J Clin Pract; 2012 May; 66(5):465-76. PubMed ID: 22512606
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
[TBL] [Abstract][Full Text] [Related]
13. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.
Stehouwer CD; Gall MA; Twisk JW; Knudsen E; Emeis JJ; Parving HH
Diabetes; 2002 Apr; 51(4):1157-65. PubMed ID: 11916939
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.
Greaves M; Malia RG; Goodfellow K; Mattock M; Stevens LK; Stephenson JM; Fuller JH
Diabetologia; 1997 Jun; 40(6):698-705. PubMed ID: 9222650
[TBL] [Abstract][Full Text] [Related]
15. The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives.
Gómez JM; Vila R; Catalina P; Soler J; Badimón L; Sahún M
Glycoconj J; 2008 Aug; 25(6):573-9. PubMed ID: 18347976
[TBL] [Abstract][Full Text] [Related]
16. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.
Landstedt-Hallin L; Arner P; Lins PE; Bolinder J; Olsen H; Groop L
Diabet Med; 1999 Oct; 16(10):827-34. PubMed ID: 10547209
[TBL] [Abstract][Full Text] [Related]
17. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
Becker A; van der Does FE; van Hinsbergh VW; Heine RJ; Bouter LM; Stehouwer CD
Neth J Med; 2003 Apr; 61(4):129-36. PubMed ID: 12852722
[TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
19. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.
Jain SK; Nagi DK; Slavin BM; Lumb PJ; Yudkin JS
Diabet Med; 1993; 10(1):27-32. PubMed ID: 8435984
[TBL] [Abstract][Full Text] [Related]
20. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Osei K; Falko JM
Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
